Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8886026 | 0.82 | PNP (0.35) | PNPPARP1ABL1RIN1ATAD2 | |
| SCHEMBL20866 | 0.81 | ATAD2 (0.41) | PNPALDH1A1ATAD2LMNACYP1A2 | |
| SCHEMBL2983845 | 0.81 | PNP (0.34) | PNPPARP1ABL1RIN1ATAD2 | |
| SCHEMBL1828928 | 0.81 | PNP (0.34) | PNPPARP1ALDH1A1ABL1RIN1 | |
| SCHEMBL20576 | 0.81 | PNP (0.34) | PNPPARP1ABL1RIN1ATAD2 | |
| SCHEMBL6168437 | 0.81 | PNP (0.34) | PNPPARP1ABL1RIN1ATAD2 | |
| SCHEMBL1843775 | 0.81 | PNP (0.34) | PNPPARP1ABL1RIN1ATAD2 | |
| SCHEMBL2051359 | 0.81 | PNP (0.34) | PNPPARP1ABL1RIN1ATAD2 | |
| SCHEMBL9960806 | 0.79 | PNP (0.38) | PNPPARP1ABL1RIN1LMNA | |
| SCHEMBL7812591 | 0.78 | ABL1 (0.33) | PNPPARP1ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217257-A1 | ENGINEERED CIRCULARIZED PEGRNAS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20240309370-A1 | METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-09-19 | — | — | US | disclosed |
| US-11795580-B2 | Molecules for verifying oligonucleotide directed combinatorial synthesis and methods of making and using the same | HAYSTACK SCIENCES CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-20200332441-A1 | MOLECULES FOR VERIFYING OLIGONUCLEOTIDE DIRECTED COMBINATORIAL SYNTHESIS AND METHODS OF MAKING AND USING THE SAME | INSITRO, INC. | 2020-10-22 | — | — | US | disclosed |
| CN-111566096-A | Benzamide compounds and their use as herbicides | 巴斯夫欧洲公司 | 2020-08-21 | — | — | CN | disclosed |
| US-10729711-B2 | Methods for treatment using small molecule potassium-sparing diuretics and natriuretics | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3619340-A1 | MOLECULES FOR VERIFYING OLIGONUCLEOTIDE DIRECTED COMBINATORIAL SYNTHESIS AND METHODS OF MAKING AND USING THE SAME | Haystack Sciences Corporation (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20190192544-A1 | METHODS FOR TREATMENT USING SMALL MOLECULE POTASSIUM-SPARING DIURETICS AND NATRIURETICS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-27 | — | — | US | disclosed |
| CN-109563052-A | 5-amino-2, 3-dihydrothiazine-1, 4-dione crystals | 麦翠奥制药公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109071461-A | The method for preparing 5- amino -2,3- dihydro thiazine -1,4- diketone crystalline solid | 麦翠奥制药公司 | 2018-12-21 | — | — | CN | disclosed |
| US-7799524-B2 | Substrates for O6-alkylguanina-DNA alkyltransferase | Ecole Polytechnique Ferdeale de Lausanne (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20100041742-A1 | RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES | YALE UNIVERSITY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100037399-A1 | Aldehyde reduction in aqueous coating and leather finishing compositions | ROHM AND HAAS COMPANY | 2010-02-18 | — | — | US | disclosed |
| EP-2028280-A1 | Aldehyde Reduction In Aqueous Coating And Leather Finishing Compositions | Rohm and Haas Company (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1730158-A2 | METHODS AND COMPOSITIONS FOR IN VITRO AND IN VIVO USE OF PARALLEL STRANDED HAIRPINS AND TRIPLEX STRUCTURES AS NUCLEIC ACID LIGANDS | Cygene, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060024775-A1 | Substrates for o6-alkylguanina-dna alkyltransferase | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL). (CH) | 2006-02-02 | — | — | US | disclosed |
| WO-2005067437-A2 | METHODS AND COMPOSITIONS FOR IN VITRO AND IN VIVO USE OF PARALLEL STRANDED HAIRPINS AND TRIPLEX STRUCTURES AS NUCLEIC ACID LIGANDS | CYGENE, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-1546371-A1 | SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031405-A1 | SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2004-04-15 | — | — | WO | disclosed |
| EP-0310365-A1 | Engine seal compatible dispersant for lubricating oils | AMOCO CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024775-A1 | Substrates for o6-alkylguanina-dna alkyltransferase | AGT, OGG1, NUDT1 | PNP 176/4885PARP1 3937/4885ALDH1A1 1497/4885 |
| US-10729711-B2 | Methods for treatment using small molecule potassium-sparing diuretics and natriuretics | PNP, GMPS, SLC5A1 | PNP 1/4885PARP1 1264/4885ALDH1A1 1156/4885 |
| US-20190192544-A1 | METHODS FOR TREATMENT USING SMALL MOLECULE POTASSIUM-SPARING DIURETICS AND NATRIURETICS | PNP, GMPS, SLC5A1 | PNP 1/4885PARP1 1264/4885ALDH1A1 1156/4885 |
| US-20100041742-A1 | RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES | NSUN3, RNGTT, SRRT | PNP 74/4885PARP1 3653/4885ALDH1A1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.